The invention relates to develop a stable, combination of terbutaline sulphate and ambroxol hydrochloride pharmaceutical compositions of syrup for treatment of bronchial asthma. This syrup is stabilized against degradation of the active ingredients by formulating with specific amount of thickening agent in ...
Currently marketed dosage forms of terbutaline sulphate are in the form of tablets at 2.5 mg and 5 mg dosage strengths, and a syrup at 0.3 mg/ml. Terbutaline sulphate is indicated for the relief of bronchospasm associated with chronic obstructive pulmonary disease for the prevention of and rever...
硫酸特布他林吸入粉雾剂 | Terbutaline Sulphate Powder for Inhalation | 特布他林 | 上市 硫酸特布他林雾化吸入用溶液 | Terbutaline Sulfate Nebuliser Solution | 特布他林 | AstraZeneca AB | 上市 硫酸特布他林口服溶液 | Terbutaline Sulfate Oral Solution | 特布他林 | 撤市 硫酸特布他林片 |...
The invention relates to develop a stable, combination of terbutaline sulphate and ambroxol hydrochloride pharmaceutical compositions of syrup for treatment of bronchial asthma. This syrup is stabilized against degradation of the active ingredients by formulating with specific amount of thickening agent in ...
The invention relates to develop a stable, combination of terbutaline sulphate and ambroxol hydrochloride pharmaceutical compositions of syrup for treatment of bronchial asthma. This syrup is stabilized against degradation of the active ingredients by formulating with specific amount of thickening agent in ...